Tracking the IDYA option chain helps you see every strike and expiry on Ideaya Biosciences Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Ideaya Biosciences Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of IDYA options activity at a glance. Use our scanner to monitor the IDYA option chain in real time and filter for the IDYA options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For IDYA stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the IDYA option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where IDYA stock options are being actively traded and where they are not.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.
The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Ideaya Biosciences Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen IDYA options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of IDYA stock options — let the full option chain come to you, pre-filtered and ready to trade.
